Abstract
We have developed a PCR-based method, called methylation-sensitive restriction fingerprinting (MSRF), to screen changes in DNA methylation in breast carcinoma. Two hypermethylation-containing fragments, HBC-1 (for 'hypermethylation in breast cancer') and HBC-2, were identified in the amplified breast tumor DNA relative to the amplified normal breast DNA of a patient. Nucleotide sequence analysis revealed no significant matches between the sequence of HBC-1 and the known sequences in the GenBank database, whereas the sequence of HBC-2 matched the upstream region of an antisense WTI (Wilms' tumor suppressor gene) promoter. The methylation status in the breast tumor DNA from this patient was confirmed by Southern hybridization using HBC-1 and HBC-2 as probes, respectively. Further analysis showed that HBC-1 was methylated aberrantly in 90% (17 of 19 patients) of the primary breast carcinomas examined. This study demonstrates that MSRF provides a useful means for screening aberrant changes in DNA methylation during tumorigenesis. The commonly methylated fragments identified by MSRF could potentially supplement pathological markers currently used for cancers and additionally lead to the discovery of novel methylated tumor suppressor genes.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1030-1034 |
| Number of pages | 5 |
| Journal | Cancer Research |
| Volume | 57 |
| Issue number | 6 |
| State | Published - 1997 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Identification of DNA methylation markers for human breast carcinomas using the methylation-sensitive restriction fingerprinting technique. / Huang, Hui-ming; Laux, Douglas E.; Hamlin, Brian C.; Tran, Phuong; Tran, Hoa; Lubahn, Dennis B.
In: Cancer Research, Vol. 57, No. 6, 1997, p. 1030-1034.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Identification of DNA methylation markers for human breast carcinomas using the methylation-sensitive restriction fingerprinting technique
AU - Huang, Hui-ming
AU - Laux, Douglas E.
AU - Hamlin, Brian C.
AU - Tran, Phuong
AU - Tran, Hoa
AU - Lubahn, Dennis B.
PY - 1997
Y1 - 1997
N2 - We have developed a PCR-based method, called methylation-sensitive restriction fingerprinting (MSRF), to screen changes in DNA methylation in breast carcinoma. Two hypermethylation-containing fragments, HBC-1 (for 'hypermethylation in breast cancer') and HBC-2, were identified in the amplified breast tumor DNA relative to the amplified normal breast DNA of a patient. Nucleotide sequence analysis revealed no significant matches between the sequence of HBC-1 and the known sequences in the GenBank database, whereas the sequence of HBC-2 matched the upstream region of an antisense WTI (Wilms' tumor suppressor gene) promoter. The methylation status in the breast tumor DNA from this patient was confirmed by Southern hybridization using HBC-1 and HBC-2 as probes, respectively. Further analysis showed that HBC-1 was methylated aberrantly in 90% (17 of 19 patients) of the primary breast carcinomas examined. This study demonstrates that MSRF provides a useful means for screening aberrant changes in DNA methylation during tumorigenesis. The commonly methylated fragments identified by MSRF could potentially supplement pathological markers currently used for cancers and additionally lead to the discovery of novel methylated tumor suppressor genes.
AB - We have developed a PCR-based method, called methylation-sensitive restriction fingerprinting (MSRF), to screen changes in DNA methylation in breast carcinoma. Two hypermethylation-containing fragments, HBC-1 (for 'hypermethylation in breast cancer') and HBC-2, were identified in the amplified breast tumor DNA relative to the amplified normal breast DNA of a patient. Nucleotide sequence analysis revealed no significant matches between the sequence of HBC-1 and the known sequences in the GenBank database, whereas the sequence of HBC-2 matched the upstream region of an antisense WTI (Wilms' tumor suppressor gene) promoter. The methylation status in the breast tumor DNA from this patient was confirmed by Southern hybridization using HBC-1 and HBC-2 as probes, respectively. Further analysis showed that HBC-1 was methylated aberrantly in 90% (17 of 19 patients) of the primary breast carcinomas examined. This study demonstrates that MSRF provides a useful means for screening aberrant changes in DNA methylation during tumorigenesis. The commonly methylated fragments identified by MSRF could potentially supplement pathological markers currently used for cancers and additionally lead to the discovery of novel methylated tumor suppressor genes.
UR - http://www.scopus.com/inward/record.url?scp=0030888263&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030888263&partnerID=8YFLogxK
M3 - Article
C2 - 9067264
AN - SCOPUS:0030888263
VL - 57
SP - 1030
EP - 1034
JO - Cancer Research
JF - Cancer Research
SN - 0008-5472
IS - 6
ER -